4.5 Review

Treatment of Eosinophilic Esophagitis: Diet or Medication?

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jaip.2021.07.029

Keywords

Esophagus; Eosinophil; Food antigen; Diet; Proton pump inhibitor; Corticosteroid; Biologic; Fibrosis; Remodeling

Funding

  1. National Institutes of Health [U54-AI117804, R01-AI140133, R01-ES031940, R01-AI092135, R21-AI154353, K24-AI135034, R01-DK114457]
  2. American Partnership for Eosinophilic Disorders/American Academy of Allergy, Asthma, and Immunology

Ask authors/readers for more resources

Eosinophilic esophagitis (EoE) is a chronic disease triggered by antigens, with increasing prevalence in children and adults, leading to complications if left untreated. There have been new clinical trials for EoE therapies, including elimination diets, proton pump inhibitors, swallowed topical corticosteroids, and biologics, with a need for future trials to tailor therapies to individual patients.
Eosinophilic esophagitis (EoE) is an antigen-triggered chronic disease of increasing prevalence in children and adults. Untreated or therapy-resistant EoE leads to complications of esophageal food impactions and luminal narrowing. The past decade has seen a number of new clinical trials for EoE therapies including elimination diets, proton pump inhibitors, swallowed topical corticosteroids, and biologics. In this review, we comment on the current state of the art for dietary and pharmacologic management of EoE and the need for future clinical trials to help tailor therapies to individual patients with this chronic disease. (C) 2021 American Academy of Allergy, Asthma & Immunology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available